NeoGenomics Laboratories

NeoGenomics Laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. We work every day to achieve our common purpose of saving lives by improving patient CARE through Communication, Accuracy, Reliability, and Efficiency. Our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor FISH testing with the largest menu of technical-only services available; 10-color flow cytometry; IHC supported by an extensive antibody library; and nearly 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. Our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out FISH, flow cytometry, and/or IHC. NeoGenomics’ extremely fast test development cycle means we are highly responsive to therapy development and guideline changes, and test design always involves a balance of convention and innovation. We support clients in many cancer-related market segments, to include: hospital and private pathology laboratories, office-based oncologists, CRO / Biopharmaceutical development organizations, academic institutions / teaching hospitals, and several more.
Company Growth (employees)
Type
Public
HQ
Fort Myers, US
Founded
2002
Size (employees)
938 (est)+11%
NeoGenomics Laboratories was founded in 2002 and is headquartered in Fort Myers, US

NeoGenomics Laboratories Office Locations

NeoGenomics Laboratories has offices in Fort Myers, Nashville, Tampa, Irvine and in 1 other location
Fort Myers, US (HQ)
9 12701 Commonwealth Dr
Fresno, US
400 30 River Park Pl W
Irvine, US
100 5 Jenner
Tampa, US
228 10002 Princess Palm Ave
Nashville, US
20 618 Grassmere Park

NeoGenomics Laboratories Data and Metrics

NeoGenomics Laboratories Financial Metrics

NeoGenomics Laboratories's revenue was reported to be $61.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

61.7 m

Gross profit (Q1, 2017)

27.2 m

Gross profit margin (Q1, 2017), %

44%

Net income (Q1, 2017)

(654 k)

EBIT (Q1, 2017)

(115 k)

Market capitalization (17-Aug-2017)

734.6 m

Cash (31-Mar-2017)

11 m
NeoGenomics Laboratories's current market capitalization is $734.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

66.5 m87.1 m99.8 m244.1 m

Revenue growth, %

31%15%145%

Cost of goods sold

34.7 m46.4 m56 m133.7 m

Gross profit

31.7 m40.7 m43.8 m110.4 m

Gross profit Margin, %

48%47%44%45%

Operating expense total

28.6 m38.5 m49.4 m107.8 m

EBIT

3.2 m2.2 m(5.6 m)2.6 m

EBIT margin, %

5%3%(6%)1%

Interest expense

854 k

Pre tax profit

1.3 m

Income tax expense

152 k157 k(2 m)(1.7 m)

Net Income

2 m1.1 m(2.5 m)(5.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

20.7 m23.2 m23 m24.4 m25.1 m59.7 m63.1 m60.8 m61.7 m

Cost of goods sold

10.4 m12.9 m13.5 m13.6 m14 m32.5 m34.5 m33.4 m34.5 m

Gross profit

10.2 m10.3 m9.5 m10.8 m11.2 m27.2 m28.6 m27.3 m27.2 m

Gross profit Margin, %

50%44%41%44%44%46%45%45%44%

Sales and marketing expense

3.2 m3 m2.9 m2.9 m2.7 m5.8 m6.3 m6 m5.6 m

R&D expense

633 k1 m669 k803 k871 k1.4 m1.3 m967 k862 k

General and administrative expense

5.9 m6.4 m6.5 m7.1 m7.4 m18 m18.8 m19 m20.8 m

Operating expense total

9.7 m10.4 m10.1 m10.8 m11.1 m25.3 m26.4 m26 m27.3 m

EBIT

578 k(73 k)(561 k)28 k114 k1.9 m2.2 m1.4 m(115 k)

EBIT margin, %

3%(0%)(2%)0%0%3%3%2%(0%)

Interest expense

1.6 m1.4 m1.5 m1.4 m

Pre tax profit

325 k(756 k)(161 k)(125 k)

Income tax expense

51 k5 k15 k20 k174 k332 k(6 k)(825 k)

Net Income

376 k85 k(761 k)(937 k)(1.1 m)155 k568 k500 k(654 k)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

4.8 m33.7 m23.4 m12.5 m

Accounts Receivable

18.7 m20.5 m48.9 m55.5 m

Inventories

2.3 m2.6 m5.1 m6.3 m

Current Assets

27.5 m58.7 m99 m78.8 m

PP&E

15.1 m

Goodwill

2.9 m146.4 m147 m

Total Assets

39.9 m81.1 m368 m337.1 m

Accounts Payable

4.2 m6.3 m12.5 m16.8 m

Current Liabilities

14.3 m14.6 m40.1 m38.1 m

Non-Current Liabilities

89.8 m112.4 m

Total Liabilities

129.8 m150.5 m

Additional Paid-in Capital

42.2 m79.8 m231.4 m216.1 m

Retained Earnings

(20.5 m)(19.4 m)(21.9 m)(52.5 m)

Total Equity

21.7 m60.4 m209.5 m163.7 m

Financial Leverage

1.8 x1.3 x1.8 x2.1 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

33 m34 m19.3 m21.8 m28.9 m11 m

Accounts Receivable

21.1 m21.6 m50.1 m53.5 m50.2 m61.7 m

Inventories

3.4 m3 m5.3 m5.5 m6 m6 m

Current Assets

59.6 m60.9 m81.2 m87.5 m92.6 m84.6 m

Goodwill

2.9 m2.9 m146.2 m146.2 m146.2 m147 m

Total Assets

83 m83.7 m346.8 m351.6 m355.4 m343.6 m

Accounts Payable

6.1 m5 m15.3 m13.4 m14 m20.6 m

Current Liabilities

15.1 m15.3 m34.3 m35 m35.4 m39.9 m

Non-Current Liabilities

7 m6.6 m72.4 m73.2 m73.9 m109.7 m

Additional Paid-in Capital

81.1 m82.3 m233.4 m236.2 m239 m217.6 m

Retained Earnings

(20.3 m)(20.5 m)(27.5 m)(32.6 m)(38.3 m)(49.1 m)

Total Equity

60.9 m61.8 m206 m203.6 m200.8 m168.6 m

Financial Leverage

1.4 x1.4 x1.7 x1.7 x1.8 x2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

2 m1.1 m(2.5 m)(5.7 m)

Depreciation and Amortization

4.2 m7.1 m23.2 m

Inventories

(229 k)(896 k)(1.1 m)

Cash From Operating Activities

2.2 m9.5 m6.4 m21.5 m

Purchases of PP&E

(2 m)(3.8 m)(2.2 m)(7.5 m)

Cash From Investing Activities

(2 m)(9.6 m)(75.2 m)(6.5 m)

Cash From Financing Activities

2.8 m29 m58.5 m(25.9 m)

Interest Paid

1.1 m981 k911 k5.4 m

Income Taxes Paid

17 k177 k25 k290 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

376 k85 k(761 k)(937 k)(1.1 m)155 k568 k500 k(654 k)

Depreciation and Amortization

2.4 m3.9 m5.6 m11 m17 m5.7 m

Inventories

21 k(800 k)(351 k)(437 k)(844 k)

Accounts Payable

(1.1 m)(41 k)2 k

Cash From Operating Activities

5.3 m8.5 m(787 k)1.9 m4.3 m7.1 m12.1 m21.7 m(1.7 m)

Purchases of PP&E

(2 m)(2.7 m)(842 k)(1.2 m)(1.7 m)(1 m)(3.4 m)(5.3 m)(3 m)

Cash From Investing Activities

(2 m)(8.5 m)(842 k)(1.2 m)(1.7 m)(1 m)(3.4 m)(5.3 m)(3 m)

Cash From Financing Activities

(3.1 m)29.6 m(812 k)(1.5 m)(2.3 m)(10.2 m)(10.3 m)(10.9 m)3.2 m

Interest Paid

498 k770 k212 k417 k672 k1.4 m2.7 m4 m1.3 m

Income Taxes Paid

170 k170 k5 k20 k20 k207 k222 k228 k5 k
USDY, 2017

Revenue/Employee

72.6 k

Financial Leverage

2 x

NeoGenomics Laboratories Market Value History

Traffic Overview of NeoGenomics Laboratories

NeoGenomics Laboratories Online and Social Media Presence

NeoGenomics Laboratories Company Life and Culture

You may also be interested in